NeuroInsights unveils expanded fourth edition of comprehensive market analysis and strategic investment report at Neurotech Industry Conference
SAN FRANCISCO and BOSTON, May 8 /PRNewswire/ -- NeuroInsights, the neurotech market authority, announced today the release of the organization's fourth annual comprehensive investment guide and market analysis of the global neurological disease and psychiatric illness markets. Unveiled during the annual Neurotech Industry Investing and Partnering Conference in Boston, this 400-page report enables investors, companies and governments to assess opportunities, calculate risks and understand the dynamics of this continually changing market.
The Neurotechnology Industry 2008 Report: Drugs, Devices and Diagnostics for the Brain and Nervous System tracks market movements that help guide strategic business development and investment decisions in neurotech. This year's report provides an in-depth look at more than 16 brain and nervous system disorders and treatments in development at over 500 public and private companies, including: Alzheimer's disease, addiction, ADHD, anxiety, depression, epilepsy, migraine, mild cognitive impairment, multiple sclerosis, obesity, pain, Parkinson's disease, schizophrenia, age-related macular degeneration, sensory disorders, sleep disorders, stroke and traumatic brain injury. Corporate financing, market activity, growth drivers and global industry conditions that make up the obstacles and opportunities facing the industry are fully assessed with detailed insights.
Specific findings from the Neurotechnology Industry 2008 Report show
that in 2007:
-- Brain-related illnesses represent the largest unmet medical market with
two billion people worldwide
-- Venture capital investment in neurotechnology reached an all-time high
at $1.77 billion
-- More than 250 investors participated in neurotech financings
-- Global neurotech indu
Copyright©2008 PR Newswire.
All rights reserved